BioSpace News Archive

Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced its financial results for the first quarter ended March 31, 2020.

Omeros Corporation announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2020, which include:

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is expanding capacity for viral vector development and manufacturing services with construction of a new commercia

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the appointment of Joseph Truitt as Chief Executive Officer. Mr. Truitt was appoint

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, to expand COVID-19 antibody testing to more than 20 Quest

TORONTO, May 11, 2020 /PRNewswire/ - Portage Biotech Inc., is pleased to announce that it has made an additional €900k investment in its associate, Stimunity, the Paris-based cancer immunotherapy company focused on STING.

Reported positive top-line data from AXA1125-003, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation observed in subjects with NAFLD receiving AXA1125 Completed enrollment of AXA1665-002, with data readout expected in Q3 2020 Announced AXA2678 patent issuance and oral presentation at ICSFR Launched new corporate website at www.axcellahealth.com CAMBRIDGE, Mass.--( BUSINE

Decibel Therapeutics to Present at the 23 rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Presentations will showcase data on the potential of gene circuits to precisely target cancer and new preclinical data on SENTI-101

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2020 and provided an update on clinical developments: On May 4, 2020, CEL-SCI announced it has been notified that it reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation for its pivotal Phase 3 head